Twitter Facebook LinkedIn WhatsApp Press Releases (-) Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2021 March 4, 2021 argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update March 2, 2021 argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis February 25, 2021 argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021 February 5, 2021 argenx announces closing of global offering February 4, 2021 argenx announces full exercise of underwriters’ option to purchase additional ADSs February 2, 2021 argenx raises $1.0 billion in gross proceeds in a global offering February 2, 2021 argenx Issues Statement Concerning Efgartigimod February 1, 2021 argenx announces launch of proposed global offering February 1, 2021 argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis January 8, 2021 argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline January 6, 2021 argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China January 4, 2021 argenx to Present at 39th Annual J.P. Morgan Healthcare Conference Pagination First page « First Previous page ‹ Previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page Next › Last page Last »
